Robert Zeldin has joined gene therapy developer MeiraGTx (NASDAQ: MGTX) as its chief medical officer. Most recently he held the same role at Immunovant (NASDAQ: IMVT). Prior Zeldin served as CMO at Acceleron Pharma (NASDAQ: XLRN) and at Ablynx. His experience also includes time at Stallergenes, Novartis (NYSE: NVS), and Merck, as well as a stint with the FDA prior to entering industry.
MeiraGTx, of New York and London, recently began planning a Phase 3 trial for one of its clinical-stage programs, a potential treatment for an inherited condition that causes progressive vision loss it is developing with partner Johnson & Johnson (NYSE: JNJ).